Brian K. Shoichet

University of California, San Francisco
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (14)

As virtual libraries have expanded into the tens of billions via make-on-demand chemistry, their similarity to metabolites, natural products, and drugs (“bio-like” molecules) has rapidly diminished. Despite this divergence, molecular docking of these ultra-large libraries has yielded molecules at higher experimental hit-rates and with improved affinities. The structural divergence from bio-like space raises the possibility that molecules from these ultra-large libraries have improved selectivity. Just as plausibly, if hit-rates on-target are divorced from similarity to bio-like molecules, so too may be selectivity against off-targets. Here, we test whether docking hits for the 5-HT 2A serotonin receptor from ultra-large libraries are more selective than those from smaller and more bio-like “in-stock” libraries. Chemoinformatic similarity predicts that docking actives from the in-stock library have more off-targets than the more chemically novel hits emerging from docking the ultra-large library. This may reflect the bias of the known, however, as when tested experimentally at scale against 318 GPCRs, both 16 agonists from the ultra-large library and 20 actives from the in-stock library had similar numbers of off-targets. While the ultra-large library hits are more sub-type selective for the 5-HT 2A over the 5-HT 2B and 5-HT 2C receptors, overall these results may suggest that selectivity against off-targets, like affinity and hit-rates for on-targets, is divorced from library similarity to bio-like molecules.

Year:

2026

General anesthetics are essential for invasive medical procedures; however, there remains a need for safer agents. Using a bespoke 96-well-plate format platform enabling high-throughput imaging of larval zebrafish behavior, we screened 12,000 compounds and identified an isoxazole chemotype that phenocopies the intravenous anesthetics etomidate and propofol. Its optimization via medicinal chemistry yielded a novel anesthetic that we call nidradine. This anesthetic is efficacious in both zebrafish and mice and lacks the problematic adrenal suppression characteristic of etomidate. Mechanistic studies via electrophysiology and structural biology revealed that nidradine, like etomidate and propofol, is a positive allosteric modulator of the GABA A receptor. Remarkably, behavioral assays in mice demonstrate that nidradine differs from most general anesthetics in that it also produces analgesia.

Year:

2026

The macrodomain of severe acute respiratory syndrome coronavirus 2 nonstructural protein 3 is required for viral pathogenesis and is an emerging antiviral target. We previously performed an x-ray crystallography–based fragment screen and found submicromolar inhibitors by fragment linking. However, these compounds had poor membrane permeability and liabilities that complicated optimization. Here, we developed a shape-based virtual screening pipeline—FrankenROCS. We screened the Enamine high-throughput collection of 2.1 million compounds, selecting 39 compounds for testing, with the most potent binding with a 130 μM median inhibitory concentration (IC 50 ). We then paired FrankenROCS with an active learning algorithm (Thompson sampling) to efficiently search the Enamine REAL database of 22 billion molecules, testing 32 compounds with the most potent binding with a 220 μM IC 50 . Further optimization led to analogs with IC 50 values better than 10 μM. This lead series has improved membrane permeability and is poised for optimization. FrankenROCS is a scalable method for fragment linking to exploit synthesis-on-demand libraries.

Year:

2025

The main protease (M Pro ) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a validated drug target. Starting with a lead-like dihydrouracil chemotype identified in a large-library docking campaign, we improved M Pro inhibition >1000-fold by engaging additional M Pro subsites and using a latent electrophile to engage Cys 145 . Advanced leads from this series show pan-coronavirus antiviral activity, low clearance in mice, and for AVI-4773 , a rapid reduction in viral titers >1,000,000 after just three doses. Both compounds are well distributed in mouse tissues, including brain, where concentrations >1000× the 90% effective concentration are observed 8 hours after oral dosing for AVI-4773 . AVI-4516 shows minimal inhibition of major cytochrome P450s and human proteases. AVI-4516 also exhibits synergy with the RNA-dependent RNA polymerase inhibitor, molnupiravir, in cellular infection models. Related analogs strongly inhibit nirmatrelvir-resistant M Pro mutant virus. The properties of this chemotype are differentiated from existing clinical and preclinical M Pro inhibitors and will advance therapeutic development against emerging SARS-CoV-2 variants and other coronaviruses.

Year:

2025

The heterotrimeric G protein–coupled serotonin receptor 5-HT 1A receptor (5-HT 1A R) mediates antinociception and may serve as a valuable target for the treatment of pain. Starting from a chemical library, we evolved ST171, a bitopic 5-HT 1A R agonist that revealed highly potent and functionally selective G i/o signaling without G s activation and marginal β-arrestin recruitment. ST171 is effective in acute and chronic pain models. Cryo–electron microscopy structures of ST171 bound to 5-HT 1A R in complex with the G i protein compared to the canonical agonist befiradol bound to complexes of 5-HT 1A R with G i or G s revealed that the ligands occupy different exo-sites. The individual binding poses are associated with ligand-specific receptor conformations that were further studied by molecular dynamics simulations, allowing us to better understand ligand bias, a phenomenon that may be crucial to the discovery of more effective and safe G protein–coupled receptor drugs.

Year:

2025

Accurate prediction of ligand-bound protein complexes and ranking them by affinity are central problems in drug discovery. While deep learning co-folding methods can help address these challenges, their evaluation has been hampered by the difficulties in assessing independence from training data and insufficiently large test sets. Here we test the ability of co-folding methods to predict the structures of 557 ligands bound to the SARS-CoV-2 NSP3 macrodomain (Mac1) that were determined after the training cut-off dates. AlphaFold3 (AF3), Boltz-2, and Chai-1 each reproduced >50% of the Mac1 ligand poses to better than 2 Å RMSD of experiment. Despite the potential for co-folding to describe protein conformational changes that stabilize ligand binding, we did not find that common conformational rearrangements, including peptide flip and a large loop opening, were recapitulated by the co-folding prediction. For AF3 and Chai-1, ligand pose prediction confidence weakly, but significantly, tracked experimental potency, while DOCK3.7 energies were only weakly correlated. Boltz-2 affinity predictions showed the strongest correlation with measured potency and, after calibration, achieved lower mean absolute error than a baseline predictor. We next assessed whether co-folding scores could rescore docking hit-lists to distinguish true ligands from non-binders among hundreds of molecules prospectively experimentally tested against AmpC β-lactamase, the dopamine D4 and the σ 2 receptors. AF3 ligand pose confidence values did not separate true ligands from high-scoring false-positives as effectively as docking scores or Boltz-2 affinity predictions did. Taken together, the modest, but independent correlations of docking score and co-folding confidence or affinity suggests that integrating physics-based and deep-learning and approaches may help with hit prioritization and subsequent optimization in structure-based ligand discovery.

Year:

2025

The rapid expansion of readily accessible compounds over the past six years has transformed molecular docking, improving hit rates and affinities. While many millions of molecules may score well in a docking campaign, the results are rarely fully shared, hindering the benchmarking of machine learning and chemical space exploration methods that seek to explore the expanding chemical spaces. To address this gap, we develop a website providing access to recent large library campaigns, including poses, scores, and in vitro results for campaigns against 11 targets, with 6.3 billion molecules docked and 3729 compounds experimentally tested. In a simple proof-of-concept study that speaks to the new library’s utility, we use the new database to train machine learning models to predict docking scores and to find the top 0.01% scoring molecules while evaluating only 1% of the library. Even in these proof-of-concept studies, some interesting trends emerge: unsurprisingly, as models train on larger sets, they perform better; less expected, models could achieve high correlations with docking scores and yet still fail to enrich the new docking-discovered ligands, or even the top 0.01% of docking-ranked molecules. It will be interesting to see how these trends develop for methods more sophisticated than the simple proof-of-concept studies undertaken here; the database is openly available at lsd.docking.org.

Year:

2025

A hallmark of neurodegenerative diseases like Alzheimer’s Disease (AD) and chronic traumatic encephalopathy (CTE) is the presence of toxic protein aggregates in neurons. In AD and CTE specifically, the protein tau forms insoluble fibrils that are hundreds of nanometers in length. Intriguingly, recent experimental structures suggest that tau ligands like the disaggregator EGCG and positron emission tomography (PET) tracers like GTP-1 and MK-6240 bind to tau fibrils in long stacks reflecting the symmetry of the protein across many binding sites. In these stacks, each ligand makes more contact with its symmetry mates than it does with the protein. To interpret the binding of these molecules and new ligands, we must understand the effects of the cooperativity between sites and the entropy coming from the number of sites. Here, we investigate a nearest-neighbors model of cooperativity and use statistical mechanics to derive binding isotherms for saturation and competition experiments. This model allows us to relate measured EC 50 so IC 50 and so values to the intrinsic binding affinity to a single site and to cooperativity across sites in ways resembling the Cheng-Prusoff Equation. Depending on the degree of cooperativity between molecular species, this model permits solutions that lack the steep binding curves expected from cooperative systems and even solutions resembling 2-site systems. We finally consider conditions for a fibril’s detection in a PET scan and practical matters of fitting this model’s parameters to data.

Year:

2025

The main protease (M Pro ) of SARS-CoV-2 is crucial for viral replication and is the target of nirmatrelvir (the active ingredient of Paxlovid) and ensitrelvir. The identification of new agents with differentiated pharmacokinetic and drug resistance profiles will increase therapeutic options for COVID-19 patients and bolster pandemic preparedness generally. Starting with a lead-like dihydrouracil chemotype from a large-library docking campaign, we improved M Pro inhibition >1,000-fold by engaging additional sub-sites in the M Pro active site, most notably by employing a latent propargyl electrophile to engage the catalytic Cys145. Advanced leads from this series, including AVI-4516 and AVI-4773 show pan-coronavirus antiviral activity in cells, very low clearance in mice, and for AVI-4773 a rapid reduction in viral titers more than a million-fold after just three doses, more rapidly and effectively than the approved drugs, nirmatrelvir and ensitrelvir. Both AVI-4516 and AVI-477 3 are well distributed in mouse tissues, including brain, where concentrations ten or fifteen-thousand times the EC 90 , respectively, are observed eight hours after an oral dose. As exemplar of the series, AVI-4516 shows minimal inhibition of major CYP isoforms and human cysteine and serine proteases, likely due to its latent–electrophilic warhead. AVI-4516 also exhibits synergy in cellular infection models in combination with the RdRp inhibitor molnupiravir, while related analogs strongly inhibit nirmatrelvir-resistant M Pro mutant virus in cells. The in vivo and antiviral properties of this new chemotype are differentiated from existing clinical and pre-clinical M Pro inhibitors, and will advance new therapeutic development against emerging SARS-CoV-2 variants and other coronaviruses. One sentence summary This manuscript describes the discovery of a new class of potent inhibitors of the SARS-CoV-2 major proteases (M Pro ) with a unique mechanism of inhibition, pan coronaviral activity in cellulo , exquisite selectivity vs. the human proteome, and exceptional in vivo efficacy in SARS-CoV-2 infection models that surpasses that of currently approved agents.

Year:

2025

Large library docking of tangible molecules has revealed potent ligands across many targets. While make-on-demand libraries now exceed 75 billion enumerated molecules, their synthetic routes are dominated by a few reaction types, reducing diversity and inevitably leaving many interesting bioactive-like chemotypes unexplored. Here, we investigate the large-scale enumeration and targeted docking of isoquinuclidines. These “natural-product-like” molecules are rare in the current libraries and are functionally congested, making them interesting as receptor probes. Using a modular, four-component reaction scheme, we built and docked a virtual library of over 14.6 million isoquinuclidines against both the µ- and κ -opioid receptors (MOR and KOR, respectively). Synthesis and experimental testing of 18 prioritized compounds found nine ligands with low µM affinities. Structure-based optimization revealed low- and sub- nM antagonists and inverse agonists targeting both receptors. Cryo-electron microscopy (cryoEM) structures illuminate the origins of activity on each target. In mouse behavioral studies, a potent member of the series with joint MOR-antagonist and KOR-inverse-agonist activity reversed morphine-induced analgesia, phenocopying the MOR-selective anti-overdose agent naloxone. Encouragingly, the new molecule induced less severe opioid-induced withdrawal symptoms compared to naloxone during withdrawal precipitation, and did not induce conditioned-place aversion, likely reflecting a reduction of dysphoria due to the compound’s KOR-inverse agonism. The strengths and weaknesses of bespoke library docking, and of docking for opioid receptor polypharmacology, will be considered.

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Collaborators (33)

R. Jeffrey Neitz

Professor

University of California, San Francisco

UNITED STATES
View details

Nevan Krogan

Professor

University of California, San Francisco

UNITED STATES
View details

Bryan L. Roth

University of North Carolina at Chapel Hill School of Medicine

UNITED STATES
View details

Michael A. Matthay

University of California

UNITED STATES
View details

Takaya Togo

Institute of Science Tokyo

JAPAN
View details

W. Patrick Walters

Relay Therapeutics Inc

UNITED STATES
View details

Michelle R. Arkin

Professor and Department Chair

University of California

UNITED STATES
View details

Matthew McCarroll

Professional Researcher

University of California, San Francisco

UNITED STATES
View details

John Irwin

Adjunct Associate Professor

UCSF

UNITED STATES
View details

Alan Ashworth

University of California, San Francisco

UNITED STATES
View details

Olivier Mailhot

Assistant Professor

Université de Montréal

CANADA
View details

Taha Taha

Assistant Professor

University of California, San Francisco

UNITED STATES
View details

Allan Basbaum

University of California

UNITED STATES
View details

William F. DeGrado

Professor

University of California

UNITED STATES
View details

Danielle Swaney

University of California, San Francisco

UNITED STATES
View details

Adam Renslo

Professor

University of California, San Francisco

UNITED STATES
View details

Ryan Hibbs

Professor

University of California, San Diego

UNITED STATES
View details

Michael Bokoch

Associate Professor

University of California, San Francisco

UNITED STATES
View details

Tamsanqa Tafara Hove

Head of image processing

University of Würzburg

GERMANY
View details

Molly Premtoon

Relay Therapeutics Inc

UNITED STATES
View details

Jonathan A. Ellman

Professor

Yale University

UNITED STATES
View details

Xi-Ping Huang

University of North Carolina at Chapel Hill

UNITED STATES
View details

Pornparn Kongpracha

University of California, San Francisco

UNITED STATES
View details

Michael Grabe

Professor

UCSF Cardiovascular Research Institute

UNITED STATES
View details

Charles S. Craik

Professor

University of California, San Francisco

UNITED STATES
View details

Melanie Ott

Professor

University of California, San Francisco

UNITED STATES
View details

Peter Gmeiner

Professor

Friedrich-Alexander Universität Erlangen-Nürnberg

GERMANY
View details

Jezrael Revalde

Senior Scientist

University of California, San Francisco

UNITED STATES
View details

Huadong Chen

University of California, San Francisco

UNITED STATES
View details

Christian Billesbølle

University of California, San Francisco

UNITED STATES
View details

James Fraser

Professor

University of California, San Francisco

UNITED STATES
View details

Bettina Böttcher

Professor

Julius-Maximilians-Universität Würzburg

GERMANY
View details

Judd Hultquist

Assistant Professor

Northwestern University

UNITED STATES
View details